News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
328,354 Results
Type
Article (19633)
Company Profile (139)
Press Release (308582)
Section
Business (105208)
Career Advice (870)
Deals (18499)
Drug Delivery (92)
Drug Development (50650)
Employer Resources (79)
FDA (7638)
Job Trends (7717)
News (185541)
Policy (17301)
Tag
Academia (726)
Alliances (27725)
Alzheimer's disease (572)
Approvals (7610)
Artificial intelligence (86)
Bankruptcy (170)
Best Places to Work (5521)
Biosimilars (68)
Biotechnology (63)
Breast cancer (79)
Cancer (667)
Cardiovascular disease (65)
Career advice (705)
Cell therapy (101)
Clinical research (41928)
Collaboration (247)
Compensation (83)
COVID-19 (1076)
C-suite (65)
Data (746)
Diabetes (99)
Diagnostics (1723)
Drug pricing (97)
Earnings (38305)
Employer resources (73)
Events (47767)
Executive appointments (233)
FDA (7940)
Funding (179)
Gene therapy (92)
GLP-1 (496)
Government (1801)
Healthcare (5860)
Infectious disease (1126)
Inflammatory bowel disease (71)
Interviews (115)
IPO (7301)
Job creations (2431)
Job search strategy (646)
Layoffs (253)
Legal (4082)
Lung cancer (101)
Manufacturing (136)
Medical device (1952)
Medtech (1955)
Mergers & acquisitions (11260)
Metabolic disorders (344)
Neuroscience (759)
NextGen Class of 2024 (2347)
Non-profit (902)
Northern California (734)
Obesity (223)
Opinion (174)
Patents (80)
People (32972)
Pharmaceutical (78)
Phase I (13085)
Phase II (17743)
Phase III (14283)
Pipeline (311)
Policy (73)
Postmarket research (1615)
Preclinical (4593)
Radiopharmaceuticals (156)
Rare diseases (156)
Real estate (3164)
Regulatory (12172)
Research institute (816)
Resumes & cover letters (138)
Southern California (673)
Startups (2005)
United States (6680)
Vaccines (216)
Weight loss (189)
Date
Last 7 days (357)
Last 30 days (1246)
Last 365 days (17632)
2024 (17240)
2023 (19641)
2022 (25866)
2021 (26646)
2020 (24882)
2019 (20058)
2018 (15588)
2017 (17253)
2016 (16203)
2015 (18802)
2014 (14787)
2013 (12553)
2012 (13484)
2011 (13817)
2010 (12739)
Location
Africa (406)
Asia (24527)
Australia (3152)
California (1653)
Canada (812)
China (175)
Colorado (70)
Connecticut (67)
Europe (50588)
Florida (241)
Illinois (165)
Indiana (124)
Japan (62)
Maryland (241)
Massachusetts (1389)
Minnesota (96)
New Jersey (647)
New York (472)
North Carolina (371)
Northern California (734)
Ohio (64)
Pennsylvania (390)
South America (603)
Southern California (673)
Texas (227)
Washington State (153)
328,354 Results for "jubilant pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Jubilant Radiopharma Announces Investment of $50 million (USD) to Expand Positron Emission Tomography (PET) Manufacturing Network
Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manufacturing facilities by adding six (6) sites in strategic locations throughout the United States.
June 24, 2024
·
2 min read
Press Releases
Jubilant Radiopharma and Simplified Imaging Solutions Announce Strategic Partnership to Support the Nuclear Medicine Community
October 30, 2024
·
5 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
Jubilant Radiopharma Introduces RUBY Mobile Solutions™
Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® in mobile settings.
June 23, 2023
·
5 min read
Jubilant Radiopharma and Cardiac Imaging, Inc. Announce Exclusive Partnership to Expand Access for Mobile Cardiac PET Offering
Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
September 29, 2023
·
6 min read
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
News
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
October 25, 2024
·
5 min read
1 of 32,836
Next
